Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects

Abstract

Figure 1 Placebo-corrected change in daytime office blood pressure over 8 h after consumption of lactotripeptide (LTP) milk on days 1 and 29 of intervention (data are presented as LsMean±s.e.m., *Po0.05).What is known about this topic K The fermented milk-derived lactotripeptides (LTP) isoleucyl-prolyl-proline and valine-prolyl-proline have been shown to lower blood pressure over several weeks in hypertensive subjects. 1-9 K LTP have been shown to possess ACE-inhibitory activity in vitro. 11 What this Study addsK This study demonstrated a modest sustained fall in daytime office systolic blood pressure already after the first dosing of LTP in high normal-to-mild hypertensive subjects. K ACE inhibiting effect of LTP could not be confirmed in vivo, although the daytime ratio of angiotensin II to angiotensin I decreased significantly. Reaserch Letter 805 Journal of Human Hypertension

Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials

“…The Dietary Approaches to Stop Hypertension trial demonstrated that a dietary pattern abundant in fruits, vegetables and low-fat dairy products can considerably reduce BP (25) . Data from Study Net change 95% CI Weight (%) Hata (1996) (6) Agerholm-Larsen (2000) (7) Kawase (2000) (8) Inoue (2003) (9) Seppo (2003) (10) Mizushima (2004) (11) Tuomilehto (2004) (12) Aihara (2005) (normotensive) (13) Aihara (2005) (hypertensive) (13) Jauhiainen (2005) (14) Engberink (2008) (15) van der Zander (2008) (16) Jauhiainen (2010) (17) Usinger ( Study Net change 95% CI Weight (%) Hata (1996) (6) Agerholm-Larsen (2000) (7) Inoue (2003) (9) Seppo (2003) (10) Mizushima (2004) (11) Tuomilehto (2004) (12) Aihara (2005) (normotensive) (13) Aihara (2005) (hypertensive) (13) Jauhiainen (2005) (14) Jauhiainen (2010) (17) Usinger (2010 Fig . 3.…”

Scientific Opinion on the substantiation of health claims related to isoleucine‐proline‐proline (IPP) and valine‐proline‐proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

“…The Panel notes that 15 RCTs Cicero et al, 2010;De Leeuw et al, 2009;Engberink et al, 2008;Itakura et al, 2001;Mizushima et al, 2004;Seppo et al, 2003;Tuomilehto et al, 2004;Turpeinen et al, 2009;Usinger et al, 2010a;Van der Zander et al, 2008a;Van der Zander et al, 2008b;Van Mierlo et al, 2009 two studies;Yoshizawa et al, 2010), of which seven were designed to detect small (3-9 mm Hg) differences in SBP De Leeuw et al, 2009;Usinger et al, 2010a;Van der Zander et al, 2008a;Van der Zander et al, 2008b;Van Mierlo et al, 2009 two studies), did not observe an effect of IPP and VPP on SBP or DBP.…”

“…In its earlier opinion (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009), the Panel had considered one meta-analysis (Xu et al, 2008), which included nine human intervention studies, as well as six additional randomised controlled trials (RCTs) (De Leeuw et al, 2009;Engberink et al, 2008;Hirota et al, 2007;Van der Zander et al, 2008a;Van der Zander et al, 2008b;Van Mierlo et al, 2009) for the scientific substantiation of the claim. The Panel noted in this assessment that although some small studies had observed a significant decrease in systolic blood pressure (SBP) with the administration of lactotripeptides at doses around 5 mg per day in untreated pre-hypertensive or moderately hypertensive subjects, these results have not been supported by large intervention trials providing daily doses of lactotripeptides in the range of 2.7 mg to 14 mg in either normotensive or untreated hypertensive subjects, and concluded that the evidence was insufficient to establish a cause and effect relationship between the consumption of IPP and VPP and maintenance of normal blood pressure.…”

“…In seven of the human intervention studies (one reported in two publications) described above Cicero et al, 2010;De Leeuw et al, 2009;Engberink et al, 2008;Mizushima et al, 2004;Usinger et al, 2010a;2010b;Van der Zander et al, 2008b) the effects of IPP and VPP on the activity of the renin-angiotensin-aldosterone system II were assessed by measuring ACE activity or changes in plasma concentrations of renin, aldosterone, angiotensin I or angiotensin. None of these studies showed a statistically significant effect between groups of IPP and VPP on parameters measured which could indicate an inhibition of ACE in vivo in humans.…”

“…In a randomised, double-blind, placebo-controlled, cross-over trial (Van der Zander et al, 2008b), 42 participants consumed a fermented milk to which IPP and VPP (8.7 mg/day) were added and a placebo milk drink (no VPP or IPP added) for four weeks each, with a four-week wash-out period in between. Office BP was measured at the beginning and end of each period.…”